In-vitro evaluation of cefpirome (HR 810), teicoplanin and four other antimicrobials against enterococci.
In-vitro activities of cefpirome (HR 810), a fourth generation cephalosporin, and teicoplanin were compared with those of ampicillin, piperacillin, and vancomycin against 56 clinical isolates of enterococci. Cefpirome had good activity with the MIC90 and MBC90 being 4 and 16 mg/l. Ampicillin and piperacillin had MBC90 of 4 and 16 mg/l. Teicoplanin was extremely active with the MIC90 being 1.6 mg/l while vancomycin had poor cidal activity with the MBC90 being 16 mg/l. A decrease in activity of cefpirome was noted when the inoculum size was increased from 10(3) to 10(7) organisms per ml. Synergy was demonstrated against most Streptococcus faecium isolates with a combination of cefpirome and gentamicin or piperacillin. Against Str. faecalis, with a similar combination, synergy was seen in less than 50% isolates. No antagonism was noted with any of the antibiotic combinations.
Chandrasekar
P H
PH
Price
S
S
Levine
D P
DP
D000667:Ampicillin / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D004338:Drug Combinations; D004357:Drug Synergism; D013293:Enterococcus faecalis / Q000187:drug effects*; D006020:Glycopeptides / Q000494:pharmacology; D066298:In Vitro Techniques; D008826:Microbial Sensitivity Tests; D010878:Piperacillin / Q000494:pharmacology; D013291:Streptococcus / Q000187:drug effects*; D017334:Teicoplanin; D014640:Vancomycin / Q000494:pharmacology; D000097572:Cefpirome
D000667:Ampicillin; D002511:Cephalosporins; D004338:Drug Combinations; D006020:Glycopeptides; D010878:Piperacillin; D017334:Teicoplanin; D014640:Vancomycin; D000097572:Cefpirome